Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15855977 | 0.82 | AHR (0.46) | SLC6A3SLC6A4AHRACACBACACA | |
| SCHEMBL28148653 | 0.81 | SLC6A3 (0.42) | SLC6A3SLC6A4AHRACACBACACA | |
| SCHEMBL21700369 | 0.78 | SLC6A3 (0.50) | SLC6A3SLC6A4AHRSLC6A2 | |
| SCHEMBL9870874 | 0.77 | AHR (0.65) | SLC6A3AHRSLC6A2 | |
| SCHEMBL6075718 | 0.77 | AHR (0.48) | SLC6A3SLC6A4AHRSLC6A2 | |
| SCHEMBL21700368 | 0.77 | AHR (0.48) | SLC6A3SLC6A4AHRSLC6A2 | |
| SCHEMBL6472818 | 0.73 | AHR (0.59) | SLC6A3SLC6A4AHRSLC6A2 | |
| SCHEMBL8927764 | 0.72 | ERN1 (0.42) | — | |
| SCHEMBL4808905 | 0.71 | AHR (0.56) | SLC6A3AHRSLC6A2 | |
| SCHEMBL27997002 | 0.68 | AHR (0.52) | SLC6A3SLC6A4AHRSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885AHR 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.